contain common functional allelic variants that affect gene expression or protein function. These include the phase II The phase II glutathione S-transferases (GSTs) GSTT1, glutathione S-transferases (GSTs) glutathione S-transferase θ1 GSTM1 and GSTP1 catalyse glutathione-mediated reduc-(GSTT1), glutathione S-transferase µ1 (GSTM1) and glutation of exogenous and endogenous electrophiles. These thione S-transferase π1 (GSTP1), which catalyse the glutaGSTs have broad and overlapping substrate specificities thione-mediated reduction of exogenous and endogenous and it has been hypothesized that allelic variants associated electrophiles with broad and overlapping substrate specificity.
with less effective detoxification of potential carcinogens
It has been hypothesized that GST functional variants associmay confer an increased susceptibility to cancer. To assess ated with less effective detoxification of potential carcinogens the role of GST gene variants in ovarian cancer developmay confer an increased susceptibility to cancer, especially in ment, we screened 285 epithelial ovarian cancer cases and the presence of environmental stresses such as smoking or 299 unaffected controls for the GSTT1 deletion (null) exposure to UV radiation (5). Deletion variants or null alleles variant, the GSTM1 deletion (null) variant and the GSTP1 codon 104 A→G Ile→Val amino acid substitution variant.
exist for the GSTT1 and GSTM1 genes and these present The frequencies of the GSTT1, GSTM1 and GSTP1 polybiochemically as a failure to express protein (6) (7) (8) . These morphic variants did not vary with tumour behaviour (low alleles are common, with the GSTT1 and GSTM1 null genotypes malignant potential or invasive) or p53 immunohistooccurring in~10-20% and 40-65%, respectively, of the chemical status. There was a suggestion that ovarian Caucasian population (9). The GSTP1 gene contains several cancers of the endometrioid or clear cell histological subpolymorphisms (10) (11) (12) . Functional significance has been type had a higher frequency of the GSTT1 and GSTM1 demonstrated for an exon 5 A→G transition resulting in a deletion genotype than other histological subgroups. The codon 104 Ile→Val amino acid substitution, with altered heat GSTT1, GSTM1 and GSTP1 genotype distributions did not stability and specific activity of the Val-containing isoform differ significantly between unaffected controls and ovarian (11, 13 (1) , no different from associated with the GSTM1 null and possibly also GSTT1 null the incidence world wide (2) . While mutations in the breast genotype, leading these authors to conclude that failure to cancer susceptibility genes BRCA1 and BRCA2 or in the detoxify products of oxidative stress may result in genetic mismatch repair genes hMSH2 and hMLH1 are responsible damage. In addition, GSTT1 and GSTM1 null genotypes were for most 'hereditary' ovarian cancers from multiple case shown to be associated with poorer survival and a reduced fluid suggest that this enzyme plays an important role in reactions were incubated in the ABI 7700 SDS PCR machine for 2 min at 50°C and 10 min at 95°C, followed by 45 two-step cycles of 15 s at 95°C
Materials and methods
and 1 min at 64°C. Genotype analysis was performed on amplified samples using the ABI PRISM 7700 software, following standard procedures. RepeatSubjects ability of the ABI PRISM 7700 SDS genotyping was assessed by re-analysis Details of cases and controls have been described previously (23). Briefly, of a subsample of 122 DNA samples, selected on the basis of DNA availability. incident cases of epithelial ovarian adenocarcinoma or cystadenoma were Successful re-amplification of samples generated confirmatory genotype results ascertained from the Royal Brisbane Hospital, Queensland, Australia from in all instances. 1985 to 1996. Only cases with low malignant potential (LMP) (n ϭ 44) or invasive (n ϭ 241) tumours were included in the analyses presented here.
p53 immmunohistochemical analysis LMP tumours have some but not all the features of malignancy. LMP Immunohistochemistry was performed as detailed by Webb et al. (27) and tumours were characterized by cellular proliferation with stratification and tumours were classified p53-positive if Ͼ10% of cells stained positive for pleiomorphism but no stromal invasion, whereas invasive tumours were p53. Tumour tissue suitable for immunohistochemical analysis was available characterized by invasion of the ovarian stroma (24) . This subseries comprised from only 83 of the ovarian cancer cases included in this study, 69 of which 183 serous, 29 mucinous, 32 endometrioid, 15 clear cell carcinoma, eight were invasive tumours. mixed Müllerian, six mixed and four undifferentiated tumours, as well as eight of unknown histology. For analysis, the mixed Müllerian and mixed Statistical analysis histologies were treated as a single mixed group. Age at diagnosis ranged The Student's t-test was used to compare the age distribution of cases and from 21 to 95 years, with an average age of 59.9 years.
controls. The Hardy-Weinberg equilibrium (HWE) assumption was assessed Controls (n ϭ 299) were adult female unrelated monozygotic twins (only for case and control groups by comparing the observed numbers of different one per pair) from a sample of 3348 twins of almost exclusively European genotypes with those expected under HWE for the estimated allele frequency descent, recruited through the volunteer National Australian Twin Registry and comparing the Pearson goodness-of-fit statistic with a χ 2 distribution on for the Semi-Structured Assessment of the Genetics of Alcoholism research 1 degree of freedom. HWE was tested for the GSTP1 locus only, since the study (25) . Control subjects were selected to match as closely as possible the GSTT1 and GSTM1 genotyping methods did not distinguish between null/ date of birth distribution observed for ovarian cancer patients, namely onenon-null heterozygotes and non-null/non-null homozygotes. Differences in the third from each of 1900-1925, 1926-1938 and 1939-1970 . Age at interview distribution of GSTT1, GSTM1 and GSTP1 genotype amongst cases stratified ranged from 30 to 90 years, with an average age of 50.9 years.
according to tumour behaviour (LMP versus invasive), histology and p53 Ethical clearance for collection of information and blood from cases and status were assessed by the χ 2 test. Logistic regression was used to assess the controls was given by the Queensland Institute of Medical Research Ethics association between genotype and age at interview or parity amongst controls Committee.
and age at onset amongst cases. Logistic regression with adjustment for age Genotype detection was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between GST genotype and ovarian cancer status. SPSS Germline DNA was prepared from whole blood as described previously (23). v.9.0 and Ottutil software were used for statistical analyses. The homozygous GSTT1 and GSTM1 gene deletion polymorphisms were screened by multiplex PCR amplification, using primer sets lying within the GSTT1 and GSTM1 genes to identify the presence of these gene sequences.
Results
An unrelated primer set homologous to the 5Ј-untranslated region of the estrogen receptor gene generating a larger control amplicon was included to GSTT1, GSTM1 and GSTP1 genotype data were successfully verify successful amplification of each DNA sample. Primer sequences and product sizes are detailed in Table I . The 10 µl reaction mix contained 30 ng generated for the majority of cases (285, 285 and 282 subjects, DNA, primers (400 nM each), deoxyribonucleotide triphosphates (200 nM), respectively) and controls (295, 297 and 292 subjects, respect-1ϫ Perkin Elmer Taq polymerase buffer, 1 U Taq polymerase and 1.5 mM ively). p53 immunohistochemical analysis was carried out on Table I . BsmA1 enzyme digestion and high resolution agarose gel electrophoresis was used to identify AA and GG homozygote DNA behaviour) were included in the histological subtype and p53 cancers (77 and 67%, respectively) compared with serous GSTP1 genotype distribution between the subgroups for tumour behaviour or histology (Table III) .
The results in Tables II and III do not (mean 59.9 versus 50.9 years, P Ͻ 0.001). Epidemiological information such as parity was not available for cases and it was thus not possible to calculate ORs with adjustment for 
GSTP1, respectively). There was no evidence for deviation from HWE for the GSTP1 locus in cases (P Ͼ 0.7 for total Tumour behaviour sample, LMP and invasive tumour forms) or controls (P ϭ 0.8). (36) Our data suggest that the endometrioid and clear cell cancers
had a greater frequency of GSTT1 and GSTM1 null genotypes a Heterogeneity assessed by the χ 2 test. (Table II) than the other histological subtypes. These histologically similar and epidemiologically related subtypes (30) (31) (32) were pooled for comparison with the control group. The pooled analyses shown in Tables II and III . There were too few LMP tumours to consider similar stratification of this group.
case group included the cases presented in Tables II-III and an additional two invasive ovarian cancer cases with mixed There was no significant difference between the GSTT1 and GSTM1 null genotype frequencies (Table II) of LMP and endometrioid/clear cell histology. After adjustment for age there was no difference in GSTP1 genotype frequency between invasive cancers. Although differences with respect to histology within invasive ovarian cancers were not statistically significant the endometrioid/clear cell cases and unaffected controls [OR (95% CI) ϭ 0.93 (0.32-2.74) for the GG genotype versus overall, the frequency of the GSTT1 null genotype was significantly greater (P ϭ 0.04) in endometrioid and clear cell AA reference]. However, both the GSTT1 and GSTM1 null genotypes were more common in invasive endometrioid/clear subtypes (29 and 33%, respectively) than in the serous subtype (17%). Endometrioid and clear cell carcinoma are considered cell cases (31 and 73%, respectively) than in controls (19 and 55%, respectively). The age-adjusted OR (95% CI) associated to be histologically and epidemiologically similar (30) (31) (32) and the serous subgroup was chosen for comparison since it is the with invasive endometrioid/clear cell tumours was 1.78 (0.88-3.60) for GSTT1 null (P ϭ 0.1) and 2.04 (1.01-4.09) for single largest histological subtype. The GSTM1 genotype showed similar but statistically significant heterogeneity across GSTM1 null (P ϭ 0.05). For analysis of the combined GSTT1ϩGSTM1 genotype using GSTT1ϩGSTM1 non-null as histological subtypes (P ϭ 0.02), also with higher frequencies of the GSTM1 null genotype in endometrioid and clear cell the reference group, the age-adjusted OR (95% CI) was 2.09 (0.61-7.19) for GSTT1 null (P ϭ 0.2), 2.24 (0.95-5.27) for too small (n ϭ 48) for reliable analysis, comparison with the GSTM1 null (P ϭ 0.07) and 3.90 (1.36-11.14) for both GSTT1 control group suggested that deletion of the GSTM1 gene and, and GSTM1 null (P ϭ 0.01).
to a lesser extent, the GSTT1 gene, might be involved in the To further investigate the histological heterogeneity of aetiology of endometrioid/clear cell ovarian cancer. This is GSTM1 genotype frequency shown in Table II , the other consistent with prior evidence that tumours of different histohistological subgroups were also compared with controls.
logy may have different aetiologies (33-35) and, specifically, There was no significant difference (χ 2 test) in the frequency that endometrioid and clear cell carcinomas are aetiologically of GSTM1 null genotype frequency for cases with serous (P ϭ related (30) (31) (32) 36, 37) . Given that endometriosis is considered 0.7), mucinous (P ϭ 0.3) or mixed (P ϭ 0.8) histology and a possible risk factor for ovarian cancer of the endometrioid the age-adjusted ORs for all of these histological subgroups or clear cell subtype (30, 31, 36, 37) , the data are also in were not significantly different from unity.
accordance with the finding from a small French study that deletion of GSTM1 and, possibly, also deletion of GSTT1 is Discussion more common in endometriosis patients than in controls (38, 39) . It is also of interest that an increased frequency of The data presented in this study of 285 ovarian cancer cases the GSTM1 null genotype was observed in a sample of 80 and 298 unaffected controls provide no evidence that the endometrial cancer patients compared with 60 controls [64 genotypes defined by the GSTT1 deletion polymorphism, versus 47%, OR (95% CI) ϭ 2.0 (0.9-4.2), P ϭ 0.06] GSTM1 deletion polymorphism or GSTP1 A→G codon 104 (40), since endometrioid and clear cell ovarian tumours are polymorphism influence the overall risk of ovarian cancer.
histologically similar to adenocarcinoma of the endometrium This study had 80% power at a significance level of 5% to (41) and ovarian cancer and endometrial cancer share epidemiodetect an overall 1.6-to 1.7-fold increased risk of ovarian logical risk factors such as low parity (42,43), obesity (44) cancer in individuals with a putative high risk GST genotype.
and oestrogen replacement therapy (32) . It is unlikely that real associations between GSTT1, GSTM1 Analysis of p53 expression was possible for a subset of the or GSTP1 genotype and ovarian cancer risk could have been ovarian cancer samples included in this study. The data from masked by differences in parity between cases and controls, 69 invasive ovarian cancer cases included in this study do not since there was no association between genotype distribution support the hypothesis of Sarhanis et al. (18) that overexpresand parity among controls. Confounding due to differences in sion of p53 is associated with the GSTM1 and, possibly, GSTT1 ethnicity is also unlikely, since controls were almost exclusively null genotypes. Our study had 97% power at a significance of European descent (25) and the same would most likely be level of 5% to detect a 2-fold difference in GSTM1 null true for the cases, given that ovarian cancer is rare in other genotype frequency between p53 negative and positive cases, population groups (2). We acknowledge that this control group as reported by Sarhanis et al. (18) . The study by Sarhanis is not a true population-based sample, but believe that these et al. (18) was of similar size with respect to p53 immunohistotwin controls, drawn from a variety of educational and sociochemical analysis (n ϭ 63), but the characteristics of the total economic backgrounds and sampled in cities across Australia ovarian cancer sample differed with respect to histology from (25) , are unlikely to be systematically genetically different the invasive sample presented here. Our study sample included from the general Australian population. more serous (64 versus 43%) and fewer endometrioid (11 There was, however, a suggestion that the GSTT1 and versus 17%), mucinous (10 versus 14%) and undifferentiated GSTM1 deletion genotypes were more common in both endo-(1 versus 19%) tumours. It is possible that the overall higher metrioid and clear cell ovarian cancer histological subtypes. Although the invasive endometrioid/clear cell subgroup was frequency of endometrioid and mucinous tumours in the study appears to be greater compared with other subtypes (Table II) . However, in our study there was no significant difference 
